# A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis

> **NCT06068478** · PHASE3 · COMPLETED · sponsor: **Tasly Pharmaceutical Group Co., Ltd** · enrollment: 472 (actual)

## Conditions studied

- Gouty Arthritis

## Interventions

- **DRUG:** Qingzhu Granules
- **DRUG:** Qingzhu Granules Placebo

## Key facts

- **NCT ID:** NCT06068478
- **Lead sponsor:** Tasly Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-07
- **Primary completion:** 2025-04-02
- **Final completion:** 2025-12-30
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068478, "A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06068478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*